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In recent years, a substantial body of evidence has emerged demonstrating that purine
and pyrimidine synthesis and metabolism play major roles in controlling embryonic and
fetal development and organogenesis. Dynamic and time-dependent changes in the
expression of purine metabolizing enzymes (such as ectonucleotidases and adenosine
deaminase) represent a key checkpoint for the correct sequential generation of the
different signaling molecules, that in turn activate their specific membrane receptors. In
neurodevelopment, Ca2+ release from radial glia mediated by P2Y1 purinergic receptors
is fundamental to allow neuroblast migration along radial glia processes, and their correct
positioning in the different layers of the developing neocortex. Moreover, ATP is involved
in the development of synaptic transmission and contributes to the establishment of
functional neuronal networks in the developing brain. Additionally, several purinergic
receptors (spanning from adenosine to P2X and P2Y receptor subtypes) are differentially
expressed by neural stem cells, depending on their maturation stage, and their activation
tightly regulates cell proliferation and differentiation to either neurons or glial cells, as well
as their correct colonization of the developing telencephalon. The purinergic control of
neurodevelopment is not limited to prenatal life, but is maintained in postnatal life, when
it plays fundamental roles in controlling oligodendrocyte maturation from precursors and
their terminal differentiation to fully myelinating cells. Based on the above-mentioned
and other literature evidence, it is now increasingly clear that any defect altering the
tight regulation of purinergic transmission and of purine and pyrimidine metabolism
during pre- and post-natal brain development may translate into functional deficits, which
could be at the basis of severe pathologies characterized by mental retardation or other
disturbances. This can occur either at the level of the recruitment and/or signaling of
specific nucleotide or nucleoside receptors or through genetic alterations in key steps
of the purine salvage pathway. In this review, we have provided a critical analysis of
what is currently known on the pathophysiological role of purines and pyrimidines during
brain development with the aim of unveiling new future strategies for pharmacological
intervention in different neurodevelopmental disorders.
Keywords: neurodevelopmental disorders, purine metabolism, enzyme deficiencies, adenosine, purine salvage
pathway, P2X7 receptors
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CONTRIBUTION OF PURINERGIC
TRANSMISSION TO THE DEVELOPMENT
OF THE CENTRAL NERVOUS SYSTEM
Neural development is a complex highly orchestrated process
involving genetic, epigenetic, and environmental events
that are crucial for shaping the architecture of the growing
brain. Proliferation and migration of glia and neurons,
followed by naturally occurring cell death of damaged or
unnecessary cells, formation of synapses, myelination of
axons, and generation of neuronal connections are indeed
critically controlled by intrinsic and environmental factors
at each stage during development (Stiles and Jernigan,
2010).
Purine and pyrimidine nucleotides are essential precursors
for nucleic acid synthesis, but their functions are not limited to
this. Purines act as metabolic signals, provide energy, control
cell growth, are part of essential coenzymes, contribute to sugar
transport and donate phosphate groups in phosphorylation
reactions (Jankowski et al., 2005; Handford et al., 2006).
Pyrimidines are involved in polysaccharide and phospholipid
biosynthesis, detoxification processes, and in protein and lipid
glycosylation (Lecca and Ceruti, 2008; Löﬄer et al., 2015). The
nervous tissue produces huge amount of ATP, which is mainly
employed to provide energy for membrane active pumps, such
as Na+/K+ ATPase, and is fundamental to sustain synaptic
transmission and the cooperation between neurons and glial
cells (Bélanger et al., 2011; Micheli et al., 2011; Harris et al.,
2012).
In the central nervous system (CNS), some purines serve
more specialized roles, not only in neurons, but also in
glial cells. Over the last 40 years it has been progressively
understood that extracellular nucleotides exert many of their
functions through the activation of ligand-gated P2X channels
(the P2X1-7 subtypes) and of G protein-coupled P2Y receptors
(the P2Y1,2,4,6,11,12,13,14 subtypes; Abbracchio et al., 2006).
Also, purine nucleosides exert receptor-mediated actions in
all mammalian tissues and systems, including the brain. The
vast majority of available data are focused on adenosine which
activates 4 G protein-coupled receptors (the A1,2A,2B,3 subtypes;
Fredholm et al., 2011), collectively referred to as P1 receptors.
An increasing body of evidence is now also pointing to specific
effects of extracellular guanosine in modulating brain functions
(for review, see Di Liberto et al., 2016). Nevertheless, the
identification and cloning of guanosine receptor have failed
so far. Overall, despite the presence of pyrimidine signaling
molecules acting on the P2Y2,4,6,14 receptor subtypes (von
Kügelgen and Hoffmann, 2016) and on the P2Y-like receptor
GPR17 (see section Involvement of the Purinergic System in
Brain Alterations Observed in Down Syndrome), this system
is referred to as the “purinergic system” (Burnstock, 2017).
P1 and P2 receptors are widely expressed throughout the
body, where they exert a variety of physiological functions,
including neurotransmission (Burnstock, 2017). Some specific
subtypes are also crucially involved in controlling brain
development.
P2Y Receptors in CNS Development
The first hints of a specific role for purinergic receptor
signaling during development came from studies in Xenopus,
where ATP degradation to ADP by E-NTPDase-2 in the
anterior neural plate, with subsequent activation of the P2Y1
receptor subtype, leads to the induction of Pax6, Rx1, and
Six3 genes. These genes encode for transcription factors
collectively referred to as eye field transcription factors
(EFTF), and are fundamental to promote and sustain eye
development (Massè et al., 2007). Altering purinergic signaling,
by either overexpressing or downregulating some of the
molecular components of this pathway, leads to abnormal eye
development, thus confirming the crucial role of extracellular
nucleotides during tissue generation and cell specification in
embryos.
Data have been further confirmed and expanded to the
mammalian brain, where it has been demonstrated that the
expression of specific P2Y receptor subtypes is plastic and tightly
controlled at different embryonic stages, and correlates with their
recruitment in controlling brain development (Oliveira et al.,
2016). For example, P2Y1 receptor-mediated calcium signaling
is fundamental for the specification of the cortical layers. At
this stage of development, daughter cells derived from neural
precursors located in the ventricular/subventricular zone start
their migration toward their final localization in the developing
cortex where they differentiate to either neurons or astrocytes
(Pino et al., 2017). Radial glial cells, a peculiar type of glial cells,
act as both neuronal progenitors in the ventricular/subventricular
zone through their asymmetric division and as “guiding sign” for
migrating cells. In fact, their long radial process extends up to the
subpial surface, and constitute a “highway” for migrating cells to
find their final localization in the correct cortical layer (Ulrich
et al., 2012; Figure 1).
Extracellular nucleotides control both radial glial cell
proliferation and migration of developing neuroblasts and
glial cells. In fact, a paracrine ATP signaling is established
through its degradation to ADP and activation of P2Y1
receptors, leading to the generation of [Ca2+]i waves that
propagate through hemichannel and gap junctions, thereby
synchronizing cell cycle and migration (Weissman et al.,
2004; Lecca et al., 2016; Figure 1). In turn, calcium waves
amplify ATP release accompanied by other neurotransmitters
and growth factors, which further contribute to drive neural
precursor migration toward developing cortical layers, where
they terminally differentiate to neurons or glial cells (Ulrich
et al., 2012).
Furthermore, extracellular ATP acts as one of the main
activity-dependent axonal signal and activates P2 receptors on
oligodendrocyte precursors cells (OPCs), which generate mature
oligodendrocytes during early post-natal development (Fields
and Stevens, 2000). ATP and uracil nucleotides interact with
growth factors to trigger specific intracellular pathways that
regulate OPC proliferation, migration, terminal maturation, and
myelination (Fumagalli et al., 2016).
Neurotransmitters and growth factors released by migrating
cells and radial glia are also fundamental for driving neuronal
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FIGURE 1 | A key role for purinergic receptors in cell cycle synchronization
and progenitor migration during CNS development. Radial glia cells originate
from neuroepithelial cells after the onset of neurogenesis, and they bear two
essential functions: (i) act as neural progenitor cells, and (ii) provide a scaffold
for migration and organization of the cortex structure. Following activation of
purinergic receptors, mostly P2Y subtypes, calcium waves sustain cell cycle
progression of migrating precursors, which are synchronized with neighboring
radial glial cells thanks to a sustained paracrine ATP release. Progenitors
eventually mature into neurons and astrocytes organizing the cortical structure.
Neurogenesis and gliogenesis initiated by purinergic signaling in the embryonic
brain continue during postnatal development. Reproduced from Ulrich et al.
(2012) with permission (license # 4213050265596) from Springer.
differentiation and maturation, and for neurite extension and
myelination. As recently elegantly reviewed (Heine et al., 2016),
the purinergic system is crucially involved also in these later
stages of neuronal development, thanks to the recruitment of
several receptor subtypes, activated by either nucleotides or
adenosine. For example, both purine P2Y1,13 and pyrimidine
P2Y2 receptor subtypes have been positively correlated to
neurite elongation, with the latter specifically linked to the αV
integrin/Rho/ROCK pathway (del Puerto et al., 2012; Peterson
et al., 2013). A significant contribution to these events is also
provided by astrocytes, and the purinergic system is also directly
involved in controlling their functions (Buffo et al., 2010; Heine
et al., 2016).
Neurogenesis and gliogenesis initiated by purinergic signaling
in the embryonic brain continue during postnatal development,
and the ventricular/subventricular zone is recognized in the
adult brain as neurogenic niche, together with the subgranular
layer of the hippocampus (Boda et al., 2017). In vitro and
in vivo studies have demonstrated that the ADP-responsive P2Y1
receptor subtype endures in its role of modulator of precursor
cell proliferation and differentiation throughout life (Suyama
et al., 2012; Boccazzi et al., 2014). Several other P2Y (and
also P2X) receptor subtypes have been found expressed in the
adult neurogenic niches (Mishra et al., 2006; Stafford et al.,
2007; Grimm et al., 2009), and could therefore contribute to
modulate neural precursor cell proliferation, differentiation, and
recruitment following brain injury, in an often-unsatisfactory
attempt to damage repair.
The Elusive Role of P2X7 Receptor in
Controlling Neuronal Functions
Although for many years the expression of P2X7 receptor in
adult brain has been confined to glial cells (i.e., astrocytes and
microglia), a lively debate is currently open on its expression
by adult neurons, with arguments both in favor and against
this statement (Illes et al., 2017; Miras-Portugal et al., 2017).
What is now widely accepted is that P2X7 is highly expressed
by neuroblasts and neural precursors during brain development,
where it inhibits cell proliferation and neurite outgrowth,
but promotes neuronal differentiation (Heine et al., 2016;
Oliveira et al., 2016). Interestingly, recent data point for a new
role of P2X7+ neuroblasts which also express high levels of
doublecortin, the typical marker of developing neurons (Boda
et al., 2017). These cells are in fact endowed with the peculiar
ability to phagocyte surrounding cells dying by programmed cell
death well before brain colonization by specialized phagocytes,
such as microglia/macrophages (Gu et al., 2015; Lovelace et al.,
2015; Figure 2). Based on these data, since programmed cell
death is a fundamental process during brain development and
shaping, leading to the elimination of unnecessary, damaged,
or exceeding cells, a new fundamental role for P2X7-mediated
purinergic signaling during embryonal life is now emerging.
Contribution of Adenosine P1 Receptors to
Neurodevelopment and Neuromodulation
Adenosine has been shown to dramatically affect embryonic
development as well. In fact, it is directly involved in the
elimination of interdigital membranes, in the apoptotic death
of clones of autoreactive lymphocytes in the thymus, and in
the morphogenetic outgrowth of vertebrate limb buds (Jacobson
et al., 1999). Moreover, the adenosine catabolizing enzyme
adenosine deaminase (ADA) is expressed at high levels in
the placenta, and its pharmacological inhibition disrupts fetal
development (Knudsen et al., 1992), thus suggesting that
developing tissues and organs are highly sensitive to increased
adenosine concentrations. A direct link with the activation of
specific P1 receptor subtypes has not been demonstrated; it is
more likely that non-receptor mediated effects are involved in
this pro-apoptotic and toxic actions of adenosine, as already
demonstrated in ADA deficiency and in other disorders (see
below; Jacobson et al., 1999). Additionally, in the developing
brain the expression of adenosine kinase, the enzyme responsible
for the rephosphorylation of adenosine to nucleotides, is
switched from neurons during life in utero to exclusive astrocytic
expression along with progressive brain maturation (Studer et al.,
2006). It is therefore clear that a tight control of adenosine
levels is fundamental for brain development and neural plasticity
(Boison et al., 2012). A role for adenosine in promoting neurite
outgrowth through the A2A receptor subtype (Heine et al., 2016),
and in fostering the differentiation of OPCs and their ability of
myelinate axons (Butt et al., 2014) has been also highlighted.
Adenosine is involved in the regulation of several signaling
pathways in CNS (Boison, 2008), acting as a neuromodulator
through multiple mechanisms, including the control of
neurotransmitter release, or via regulatory effects on glial
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FIGURE 2 | Expression and phagocytic roles for the P2X7 receptor in the developing human CNS and its contribution to Programmed Cell Death (PCD). The scheme
indicates that naturally occurring PCD is fundamental in CNS development, due to cell overproduction. It can be divided into: (i) target-independent PCD of
proliferating neural stem/precursor cells or neuroblasts, and (ii) target-dependent PCD of postmitotic neurons after establishing synaptic contact with their targets. The
phagocytosis and elimination of dead precursors (∼50–70% is eliminated by target-independent PCD prior to maturation) is mediated via the scavenger receptor
P2X7 expressed by surrounding neurobalsts. The colonization of the developing CNS parenchyma by professional phagocytes (i.e., microglia/macrophages) or the full
maturation of astrocytes occurs after 14–15 weeks of gestation (WG). Reproduced from Gu et al. (2015) under a Creative Commons (CC) license.
cells (Boison et al., 2010, 2012). As extensively reviewed
elsewhere (Fredholm et al., 2005), activation of A1 receptors
inhibits the release of neurotrasmitters, such as dopamine
and glutamate, and decreases neural excitability by inducing
post-synaptic hyperpolarization. Conversely, A2A receptors
promote neurotransmitter release. Based on these interactions
with glutamatergic and dopaminergic neurotransmission,
a role for adenosine in neurodevelopmental defects at the
basis of schizophrenia has been proposed (Lara and Souza,
2000; Lewis and Levitt, 2002; see section The Adenosine
Dysfunction Hypothesis in Neurodevelopment). A role for A2B
and A3 adenosine receptors (both expressed in brain) in neural
development still remains to be unveiled.
NEURODEVELOPMENTAL DISORDERS
ASSOCIATED TO ALTERATIONS IN
PURINE AND PYRIMIDINE METABOLISM
Defects in Nucleotide Metabolism
Purine de novo biosynthesis is a complex, energy-expensive
process. As depicted in Figure 3, it begins with the formation of
phosphoribosyl pyrophosphate (PRPP) and leads to the first fully
formed nucleotide, inosine 5′-monophosphate (IMP), which can
be subsequently converted into either AMP or GMP (Kelley and
Andersson, 2014). PRPP is also utilized to convert the nucleobase
orotic acid into uridine monophosphate (UMP), the first step
of the biosynthesis of pyrimidines. Alternatively, intracellular
nucleosides coming from the diet or from the dephosphorylation
of endogenous nucleotides can be recycled by the salvage
pathway. The catabolism of residual free bases generates uric
acid in case of purines, and β-alanine and β-aminoisobutyric
acid in case of pyrimidines to be excreted as end products. Both
de novo and salvage pathways are feedback-regulated by their
end products, whereas purine catabolism is mostly regulated
by substrate availability (Micheli et al., 2011). Only 10–30%
of the free purines generated by intracellular metabolism are
degraded or excreted (Torres and Puig, 2007), thus highlighting
the importance of nucleotide salvage, which is fundamental
in brain tissues; in addition, salvaged IMP from the liver is
transported by erythrocytes to the brain and other tissues, where
it is released for conversion to ATP or GTP (Ipata et al., 2011).
Considering the crucial roles of purines, pyrimidines, and
their derivatives in brain development (see section Contribution
of Purinergic Transmission to the Development of the Central
Nervous System), it is evident that alterations in their
synthesis, catabolism, and concentrations may lead to significant
functional consequences. Inborn errors in purine metabolism
are usually rare, and characterized by the absence or abnormal
concentrations of purine nucleotides in cells, or by the presence
of toxic intermediates in body fluids. At present, more than 35
enzyme defects of nucleotide synthesis, salvage, and catabolism
of both purines and pyrimidines have been identified, some of
which are associated with serious clinical consequences during
development (Table 1; for review see Micheli et al., 2011).
These disorders, previously considered as pediatric diseases, are
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FIGURE 3 | Schematic representation of purine and pyrimidine metabolism. Ribose-5-phosphate and carbamoyl-phosphate are the starting points of the two de
novo biosynthesis pathways. Salvage pathways are indicated with bold arrows. Monophosphate intermediates, representing the link between de novo biosynthesis
and salvage pathways, are highlighted in gray boxes. End-products of purine and pyrimidine catabolism (i.e., uric acid and β-alanine) are in white boxes. Impairment at
any enzymatic step can lead to inborn disorders. Enzymes whose altered functions have already been associated to the neurodevelopmental disorders described in
the text are indicated in red. ADA, Adenosine deaminase; ADK, Adenosine kinase; ADSL, adenylosuccinate lyase; APRT, adenine phosphorybosyl-transferase; ATIC,
AICA-ribotidetransformylase/IMP cyclohydrolase; BUP, β-ureidopropionase; DHP, dihydropyrimidinase; DPD, dihydropyrimidine dehydrogenase; GNS, guanase;
HPRT, hypoxanthine-guanine phosphorybosyl-transferase; PRPP, 5-phosphorybosyl-1-pyrophosphate; PRPS, PRPP synthetase; S-AMP, adenylosuccinate; SAICAR:
succinylaminoimidazole carboxamide ribotide; XO, xanthine oxydase; UK, uridine kinase; UMPS, UMP synthetase; UP, uridine phosphorylase.
now increasingly recognized in adults with milder phenotypes.
Although purines and pyrimidines are essential in all tissues, the
clinical outcomes of these disorders often suggest that the CNS is
more seriously affected than other organs.
In the following paragraphs, we will introduce some of
these disorders, focusing on the possible links between enzyme
alterations during development and their neurological outcomes.
Defects in Purine de Novo Biosynthesis and
Catabolism
PRPP synthetases (PRPS) catalyze PRPP synthesis from Mg-
ATP and ribose-5-phosphate, and represent the first step in
purine synthesis. Modulation of PRPS1 activity by its substrates,
inhibitors (ADP and GDP), activators (Mg2+ and organic
phosphate), and end-products determines the intracellular levels
of PRPP, an essential cofactor for both de novo biosynthesis and
salvage pathway (see section Defects in Nucleotide Metabolism;
Figure 3; Micheli et al., 2011). Thus, defects in PRPS have serious
consequences for several essential processes, such as nucleic acid
synthesis, cellular metabolism, and signaling (de Brouwer et al.,
2010).
Three isoforms of PRPS have been identified in humans,
two of which are expressed in the brain: PRPS1 and PRPS2. In
particular, altered activity of PRPS1 was associated to several
distinct diseases. The most characterized is enzyme superactivity
resulting from point mutations affecting the allosteric regions
that regulate the enzyme switching off. Purine overproduction
leads to hyperuricemia, and patients often show increased
hypoxanthine and xanthine levels in cerebrospinal fluid (Torres
et al., 2016). However, low purine nucleotide, in particular GTP,
levels are observed, since the deregulated enzyme is also unstable
and becomes inactive in anucleated or post-mitotic cells, such as
erythrocytes and brain cells, in which the enzyme turnover is low
or absent. Neurological outcomes include mental retardation,
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TABLE 1 | Description of the most relevant pathologies where an involvement of purines and pyrimidines in neurodevelopmental alterations has been hypothesized or
demonstrated.
Disease Causes and incidence Symptoms References
ADA deficiency
(ADA-SCID)
Autosomal recessive mutation in the ADA gene (20q13.12).
Estimated incidence 1:200,000-1,000,000.
• Severe immunodeficiency
• Seizures
• Autistic behaviors
Bottini et al., 2001;
Micheli et al., 2011
ADSL deficiency Autosomal recessive mutation in the ADSL gene (22q13.1).
Enzyme deficiency leads to accumulation of toxic derivatives of
adenosine in body fluids.
Rare disorder (80 patients worldwide).
• Developmental delay
• Seizures
• Hypotonia
• Autistic features
• Brain atrophy
Micheli et al., 2011;
Jinnah et al., 2013
ATIC deficiency Autosomal recessive mutation in the ATIC gene (2q35).
Accumulation of toxic derivatives of adenosine in body fluids.
One single case with complete deficiency of the ATIC enzyme was
described.
• Intellectual disabilities
• Blindness
• Epilepsy
Marie et al., 2004
Autism spectrum
disorder
Still to be clarified. The concurrence of genetic and environmental
factors has been suggested.
It manifests in the first 36 months of life.
Estimated incidence 30-60:10,000.
• Impairments in social communication
and interactions
• Stereotyped repetitive behaviors
• Affective instability
Voineagu et al., 2011;
Lauritsen, 2013
Dihydropyrimidinase
(DHP) deficiency
Autosomal recessive mutation in the DPYS gene (8q22). 11 cases
with complete DHP absence have been described. Heterozygous
subjects are asymptomatic and show some of the described
symptoms upon 5-FU administration (pharmacogenetic
syndrome).
• Developmental delay
• Epilepsy
van Kuilenburg et al., 2003,
2010;
Micheli et al., 2011
Dihydropyrimidine
dehydrogenase
(DPD) deficiency
Autosomal recessive mutation in the DPYD gene (1p21.3). Full or
partial DPD deficiency is estimated to be present in about 3%-5%
of the population. Most of them are asymptomatic. Some of the
severe outcomes were observed upon administration of 5-FU
(pharmacogenetic syndrome).
• Seizures
• Motor and mental retardation
• Autistic features
• Gastroenteric disorders
• Myelosuppression, myelopathy
van Kuilenburg et al., 2003
Down Syndrome
(DS)
Trisomy of chromosome 21 leading to the aberrant overexpression
of genes and miRNAs.
Incidence: 1:700, 1:1,000 live births.
• Broad clinical spectrum
• Platelet disorders
• Cardiac alterations
• Mental retardation
• Accelerated aging with early deposition
of β-amyloid-plaques and
Alzheimer’s-like features
Dierssen, 2012
Hereditary orotic
aciduria
(UMPS deficiency)
Autosomal recessive mutation in the UMPS gene (3q21).
Rare disorder (20 cases worldwide).
• Orotic aciduria, crystalluria,
• Megaloblastic anemia,
immunodeficiency
• Developmental delay
• Motor impairment, hypotonia
Wortmann et al., 2017
Hypophosphatasia Hypomorphic mutations in the ALPL gene, encoding TNAP
Estimated incidence: 1/100.000.
• Rickets
• Osteomalacia
• Seizures
Whyte, 2010;
Sebastián-Serrano et al., 2016
Lesch-Nyhan
syndrome
X-linked mutation in the HPRT1 gene (Xq26.2-q26.3), producing a
defective form of the enzyme. Uric acid precipitates in the body
fluids. Alteration in dopamine levels, in particular in basal ganglia.
Estimated incidence 1:500,000 (affects only males).
• Hyperuricemia, nephrolithiasis, gout
• Dystonia, choreoathetosis,
extrapyramidal symptoms
• Intellectual disability, self-injurious
behavior
Wong et al., 1996;
Ceballos-Picot et al., 2009;
Jinnah et al., 2013
PRPP synthetase
1 (PRPS1)-
deficiency
X-linked point mutation in the PRPS1 gene, with partial or
complete loss of enzymatic activity. The most severe outcome is
Arts syndrome.
Extremely rare.
• Developmental delay
• Hypotonia, ataxia, hearing impairment,
optic atrophy, peripheral neuropathy
• Premature death due to recurrent
infections
Duley et al., 2011
(Continued)
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TABLE 1 | Continued
Disease Causes and incidence Symptoms References
PRPS1-
superactivation
X-linked point mutation in the PRPS1 gene (Xq22.4), leading to
increased enzymatic activity in cells with high RNA/protein
turnover. Conversely, the mutated enzyme is unstable in neural
cells and erythrocytes, where very low residual activity was found.
Rare disorder (30 families worldwide).
• Cognitive impairment
• Ataxia
• Hypotonia
• Sensorineural deafness
• Hyperuricemia, gout, kidney failure
Duley et al., 2011
Schizophrenia Chronic and severe mental disorder with a typical onset in late
adolescence or early adulthood.
Caused by a combination of genetic susceptibility and
environmental perturbations.
Estimated incidence: 1.5:10,000.
• Positive symptoms: visual or auditory
hallucinations
• Negative symptoms: apathy, anhedonia
and alogia
• Cognitive symptoms: altered ability to
think clearly and to sustain attention
Lewis and Levitt, 2002;
McGrath et al., 2008
early-onset hypotonia, ataxia, delayed motor development,
sensorineural deafness, and optic atrophy (de Brouwer et al.,
2010). Interestingly, similar neurological symptoms are observed
in patients affected by Arts syndrome, a severe disease in which
a missense mutation completely inactivates PRPS1 (Duley et al.,
2011). Other mutations in the same enzyme are associated to
sensorineural symptoms (e.g., neuropathy, deafness) not directly
related to specific defects in neurodevelopment. There is no
univocal explanation of the variety of neurological symptoms, but
increased oxypurine production and GTP depletion in the CNS
could play an important role (de Brouwer et al., 2010).
The last steps of purine de novo biosynthesis
(see Figure 3) require the sequential activity of two
enzymes: adenosylosuccinate lyase (ADSL) and AICAR
transformylase/IMP cyclohydrolase (ATIC). ADSL catalyzes
both the conversion of succinylaminoimidazole carboxamide
ribotide (SAICA-R) into AICA-ribotide (AICAR), and of
adenylosuccinate (S-AMP) to AMP. Altered function of
ADSL leads to the accumulation of succinyl-purines in
body fluids, mainly in cerebrospinal fluid and urines, with
consequent neurotoxic effects (Jinnah et al., 2013). The clinical
manifestations of mutations in this enzyme are very diverse and
include psychomotor retardation, seizures, and autistic features.
The ratio between S-adenosine (a toxic intermediate produced
by dephosphorylation of S-AMP) and SAICAR is inversely
proportional to the onset and severity of symptoms.
ATIC deficiency, described in one single case, also leads to
the formation of toxic intermediates, mainly AICAR and its
ribosides (called ZMP, ZDP, and ZTP), with mental retardation,
epilepsy, brachycephaly, dysmorphic features, and blindness
(Marie et al., 2004). In this patient, erytrocyte ATP and AMP
concentration was lowered by 60%, but no significant changes
in other nucleotides were observed. AICAR is neurotoxic in
undifferentiated neuroblastoma cells and triggers apoptosis, and
shows a marked inhibition of carbohydrate and lipid metabolism
in the liver through the activation of AMP-dependent protein
kinase (AMPK; Garcia-Gil et al., 2006). ATIC deficiency and
consequent depletion of purines could be particularly relevant
during embryonic development and organogenesis, when de
novo synthesis is more important. This considerationmay be true
for several other defects in purine and pyrimidine metabolism
in which the link with some neurological features are not fully
clarified.
Dysfunction in ADA, the enzyme catalyzing the deamination
of adenosine to inosine (see section Contribution of Purinergic
Transmission to the Development of the Central Nervous
System), is correlated to a severe combined immunodeficiency
(named ADA-SCID). Accumulation of adenosine affects
physiological methylation reactions, induces apoptosis of
thymic lymphocytes and inhibits ribonucleotide reductase,
thus interfering with DNA synthesis and repair (Joachims
et al., 2008); these effects could explain the immunological
impairment observed in ADA-deficient patients. Neurological
symptoms, such as seizures and autistic behaviors, usually
absent in early infancy and increasing in severity with age, were
also described. Interestingly, reduced ADA activity has been
reported in the serum of autistic children, in association with
a polymorphism in the ADA gene (Bottini et al., 2001). In vivo
studies in animal models support the hypothesis of adenosine
toxicity during embryonal life, similarly to what observed in
lymphocytes (see above). Both receptor-mediated and receptor-
independent mechanisms have been demonstrated to be at the
basis of adenosine toxicity (Jacobson et al., 1999). When specific
receptor subtypes are involved, high adenosine levels may either
overactivate or inhibit cAMP signaling, thus starting a cascade of
events that leads to impaired neurotransmission (see also section
The Adenosine Dysfunction Hypothesis in Neurodevelopment).
These examples of alterations in purine biosynthesis and
catabolism clearly highlight how the blockade of the same
pathway can have distinct neurological outcomes. In some of
these disorders the concentration of purine nucleotides in body
fluids is only slightly changed, probably due to supply by the
salvage pathway.
Deficiencies in the Purine Salvage Pathway
The hypoxantine-guanine phosphoribosyl transferase (HPRT)
enzyme catalyzes the reutilization of hypoxantine and guanine in
the energetically favorable synthesis of the nucleotides IMP and
GMP, respectively, (see bold arrows in Figure 3). Any mutation
in the human HPRT1 gene, located on the X chromosome,
produces defective forms of the enzyme that are unable to
recycle nucleotides; thus, accelerated de novo biosynthesis is
Frontiers in Pharmacology | www.frontiersin.org 7 December 2017 | Volume 8 | Article 941
Fumagalli et al. Purines, Pyrimidines, and Neurodevelopmental Disorders
stimulated as a result of the accumulation of PRPP and reduced
inhibition by end-products (Deutsch et al., 2005). This unbalance
causes overproduction of uric acid that can precipitate in body
fluids with subsequent hyperuricemia, nephrolithiasis, and gout.
The most severe disorder associated with a very low residual
HPRT activity is Lesch-Nyhan syndrome, also characterized by
motor impairment, with dystonia and extrapyramidal symptoms,
intellectual disabilities, and dramatic compulsive self-mutilation
such as biting digits, lips, or buccal mucosa (Nguyen and
Nyhan, 2016). Treatment with allopurinol, an inhibitor of
xanthine oxidase, reduces plasma concentrations of uric acid,
with no effect on neurological symptoms (Deutsch et al., 2005),
suggesting that in the brainmore complexmetabolicmechanisms
are involved.
Although the pathogenesis of neurological and
neurobehavioral manifestations is not clearly understood, several
pieces of evidence support the idea that HRPT deficiency
strongly influences early development of dopaminergic
neurons (Ceballos-Picot et al., 2009; Kang et al., 2011). Post
mortem brains from Lesch-Nyhan subjects did not show any
morphological abnormality or signs of degeneration (Del Bigio
and Halliday, 2007; Göttle et al., 2014). However, voxel-based
morphometry imaging revealed a significant reduction of brain
volumes in Lesch-Nyhan patients, likely due to developmental
deficits, in particular in clusters of white matter including
the nigrostriatal dopamine pathway (Schretlen et al., 2015).
Moreover, positron emission tomography and autopsy studies
showed a 60–90% reduction in both dopamine levels and
dopamine uptake in basal ganglia of patients (Wong et al., 1996).
In accordance, neurochemical analysis revealed alterations of
brain neurotransmitters, with decreased dopaminergic synapses
in the striatum (Visser et al., 2000). All these changes were
consistent with the extrapyramidal symptoms of the syndrome.
Several authors have tried to explain the molecular
link between the altered purine metabolism and neuronal
development. It has been recently hypothesized that the excess
in hypoxantine concentrations is the trigger for subsequent
neurochemical abnormalities (Torres et al., 2016). Indeed,
normal neurons are very efficient in consuming almost all
the hypoxanthine synthesized from nucleotide catabolism
and they release virtually no hypoxanthine into the culture
medium. Due to feedback enzyme regulation, defective salvage
is counterbalanced by an increased de novo purine synthesis.
HPRT-deficient rat neuroblastoma cell line B103, used as an
experimental in vitro model of the disease, showed normal
excretion of xanthine, but hypoxanthine is not recycled to IMP,
leading to a 15-fold increase in extracellular hypoxanthine
excretion (Pelled et al., 1999). These abnormal concentrations of
hypoxantine, in turn, diminish adenosine uptake into the cells
by a competitive mechanism through equilibrative nucleoside
transporters (Prior et al., 2007) and increase extracellular
adenosine concentrations, thus prolonging the activation of
its receptors. As mentioned above, one of the main effects of
adenosine in the CNS is the inhibition of neurotransmitter
release through the A1 receptor subtype, with decreased neural
excitability by post-synaptic hyperpolarization. However,
adenosine can also induce opposite effects through the A2A
receptor (Fredholm et al., 2005). These receptor subtypes
are expressed in different areas of the developing brain,
and their timely recruitment regulates a correct integration
between excitatory and inhibitory processes. It is likely that
in Lesch-Nyhan syndrome excitatory A2A-mediated signaling
is predominant compared to A1-mediated inhibitory effects.
Thus, alterations in adenosine levels generate an imbalance
in neurotransmission, that could be responsible for some of
the symptoms observed in patients, including aggressive and
self-injurious behaviors. Moreover, in post mitotic neurons
hypoxanthine also increases the expression of the adenosine
A2A, dopamine D1, and serotonin 5-HT7 receptors further
potentiating their signaling (Torres and Puig, 2015).
Neurodevelopmental Diseases and Pyrimidine
Metabolism
Ten defects in pyrimidine metabolism have been described, but
their incidence is probably underestimated (Balasubramaniam
et al., 2014). As for purines, pyrimidine-based compounds are
ubiquitous, and this may explain the clinical heterogeneity
of the symptoms of the deficiency of specific enzymes.
Clinical manifestations include unexplained anemia, delayed
development, seizures, neonatal fitting, microcephaly, mental
retardation, and dysmorphic features.
The typical disorder of pyrimidine metabolism is orotic
aciduria, known as a megaloblastic anemia accompanied by
renal impairment, due to a deficiency in uridine monophosphate
synthetase (UMPS; see Figure 3), a bifunctional enzyme in the
de novo pyrimidine synthesis. The first reaction catalyzes the
conversion of orotate to orotidine monophosphate, thanks to
orotate phosphoribosyltransferase (OPRT) activity. In the second
step, orotidine decarboxylase (ODC) generates UMP. Very high
orotate levels (up to 400-fold compared to control subjects) are
found in urine and plasma of patients suffering from the disease
(Wortmann et al., 2017). Children with UMPS deficiency have
a strong pyrimidine starvation and, if untreated, can develop
growth retardation, intellectual disability, and epilepsy.
Interestingly, pyrimidine nucleotide starvation can be
partially rescued by exogenous administration of uridine (see
section Toward a Purinergic-Based Therapy for Congenital
Neurodevelopmental Disorders?). Indeed, dietary pyrimidines
(mainly cytosine and uracil derivatives) are able to pass into
the circulation, where they are salvaged starting from their
nucleosides (cytidine and uridine, respectively). Conversely,
most purines do not enter the bloodstream as they are converted
to uric acid during their transit across the small intestine
(Duley et al., 2011). Uridine has been utilized in clinics as an
anticonvulsant in the treatment of autism-associated seizures
(Kovács et al., 2014).
A small number of patients show specific enzymatic
deficiencies in the catabolic pathways for pyrimidines, mostly
showing with mental retardation, seizures, or both. In this
case, toxic accumulation of pyrimidines and their metabolites
were found. Dihydropirimidine dehydrogenase (DPD) catalyzes
the first step of the catabolism of pyrimidine bases, i.e.,
the reduction of uracil and thymine to dihydrouracil and
dihydrothymine, respectively. Point mutations in the DPYD gene
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lead to a defective enzyme that, in homozygous subjects, results
in thymine-uraciluria. Complete DPD-deficiency is associated
to convulsions, motor, and mental retardation in the most
severe forms, with autistic features and NMR evidence of
severe delay in brain myelination (Enns et al., 2004). Usually,
psychomotor development is normal at birth, but progressively
worsens during the first years of life with speech retardation
and various degrees of developmental delay (van Kuilenburg
et al., 2010). Heterozygous subjects are usually asymptomatic, but
can show gastroenteric disorders, myelosuppression, cerebellar
ataxia, mental deterioration, and myelopathy if treated with the
DPD substrate 5-fluorouracil (5-FU), a pyrimidine analog widely
used as antineoplastic drug. In fact, enzyme deficiency prevents
the degradation of 5-FU, whose accumulation quickly reaches
toxic concentrations (van Kuilenburg et al., 2003).
The second enzyme of pyrimidine catabolism is
dihydropirimidinase (DHP), responsible for the reversible
hydrolysis of dihydrouracil and dihydrothymine coming from
the previous step to N-carbamyl-β-alanine and N-carbamyl-β-
aminoisobutyric acid, respectively. DHP is expressed in liver and
kidney, whereas no activity was found in brain. However, DHP-
deficient subjects can show strong neurological manifestations
similar to those observed in DPD deficiency, including the
pharmacogenetic syndrome induced by 5-FU. In fact, toxic
accumulation of dihydropyrimidines was found not only in
blood, but also in cerebrospinal fluid, thus confirming that these
metabolites cross the blood-brain barrier (van Kuilenburg et al.,
2003).
Defects in Purine Metabolism and Abnormal Brain
Development: The Case of Tissue Non-specific
Alkaline Phosphatase (TNAP)
As highlighted in section Contribution of Purinergic
Transmission to the Development of the Central Nervous
System, during CNS development both extracellular nucleotides
and nucleosides are directly involved in the timely and accurate
modulation of neural precursor proliferation, migration,
and differentiation. Among the various metabolic pathways
leading to increased adenosine concentrations, a tight control
of the enzymatic processes driving adenine nucleotide
dephosphorylation is therefore mandatory to guarantee the
correct balance between these two classes of signaling molecules.
Among enzymes involved in nucleotide catabolism, tissue
non-specific alkaline phosphatase (TNAP) is peculiarly expressed
in mineralizing bones, in the kidney, and in the CNS
(Sebastián-Serrano et al., 2015). The main function of TNAP
is to hydrolyze extracellular inorganic pyrophosphate (PPi), a
potent mineralization inhibitor, thus enabling the deposition
of hydroxyapatite in bones and teeth (Sebastián-Serrano et al.,
2015). Additionally, TNAP is highly expressed at early stages of
CNS development when proliferation of neural precursors and
migration of their progeny toward their final position in the brain
take place (see also Contribution of Purinergic Transmission to
the Development of the Central Nervous System). Specifically,
strong TNAP activity is observed at embryonic day 14 in
the ventricular/subventricular zone where neural precursors are
located and reside until adulthood (Langer et al., 2007). The
direct role of TNAP in proliferation and differentiation processes
during CNS development is still elusive, but it has now become
evident that purinergic signaling plays a fundamental role in
modulating proliferation, differentiation and migration capacity
of neural precursors and of newborn neurons and glia cells (see
Contribution of Purinergic Transmission to the Development
of the Central Nervous System; Suyama et al., 2012; Boccazzi
et al., 2014). Moreover, purinergic signaling is also crucially
involved in axon guidance and growth and in the establishment
of correct synaptic contacts, and high TNAP activity has also been
documented at the stages of intensive synaptic generation and
plasticity (Sebastián-Serrano et al., 2015). Based on TNAP ability
to fine-tune the balance between extracellular nucleotides and
nucleosides, it is therefore conceivable that this enzyme might
be crucially involved in controlling the delicate phases of the
building of the correct brain architecture, and in modulating the
activation of specific purinergic receptors.
TNAP can also dephosphorylate pyridoxal-5′-phosphate (PLP,
the active form of vitamin B6) to pyridoxal, which in turn enters
the cytoplasm where it is rephosphorylated and acts as cofactor
for the synthesis of enzymes involved in the metabolism of
various neurotransmitters (e.g., GABA, serotonin; Amadasi et al.,
2007).
Based on the above-mentioned localization and activities
of TNAP, it can be speculated that defects in its expression
would lead to significant pathological outcomes. In fact,
hypomorphic mutations in the ALPL gene encoding TNAP lead
to accumulation of PPi in the extracellular matrix with deficits in
bone mineralization, causing hypophosphatasia, a heritable form
of rickets in children or osteomalacia in adults (Table 1; Whyte,
2010). Although the exact consequences of these mutations on
brain development have not been clarified yet, TNAP knock-
out mice show abnormalities in myelination and synaptogenesis
(Hanics et al., 2012), and subjects with hypophosphatasia
suffer from seizures (Whyte, 2010), thus indicating defects in
neurotransmission and/or in neurodevelopment (Fonta et al.,
2015). Recent data have now started to link these defects and
clinical manifestations to altered purinergic transmission, with
the first demonstration of a direct involvement of an aberrant
P2X7 activation in the alterations of hippocampal and cortex
structure and in the development of seizures in TNAP−/−
mice, due to high ATP concentrations as a consequence of
reduced TNAP activity (Sebastián-Serrano et al., 2016). This
observation would greatly help the development of possible new
pharmacological approaches to the pathology.
OTHER DISORDERS POTENTIALLY DUE
TO ABNORMALITIES OF PURINE
NEUROMODULATION DURING
DEVELOPMENT
Involvement of the Purinergic System in
Brain Alterations Observed in Down
Syndrome
Down Syndrome (DS) represents the most typical example of
genetic disorder associated to mental retardation. Trisomy of
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chromosome 21 leads to the pathological overexpression of
various gene products and miRNAs, but also to additional
alterations spanning from the deregulation of non-coding DNA,
the abnormal expression of non-HSA21 (non-Homo sapiens
autosome 21) genes and epigenetic modifications (for review
see Dierssen, 2012). These genetic abnormalities lead to a
consequent dysregulation of related biochemical pathways in all
tissues (Table 1; Spellman et al., 2013), but the most relevant
alterations are localized in the brain, with consequent moderate
to severe mental retardation (Dierssen, 2012). The most evident
anatomical correlates of mental retardation in DS children and
fetuses are brain hypoplasia and hypocellularity, leading to a
decreased brain size (Rachidi and Lopes, 2008). Consistent
with this observation, many groups have detected an impaired
proliferation of neural precursors and reduction in neurogenesis
in the developing neocortex, hippocampus, and cerebellum
of mouse models of DS and of DS fetuses (Contestabile
et al., 2007, 2009; Guidi et al., 2008). In the adult brain
the above-mentioned modifications also translate in reduced
spine density and impaired synaptic plasticity, paralleled by
profound alterations in several neurotransmitter pathways (i.e.,
GABA, glutamate, serotonin etc.), with a consequent imbalance
between excitatory and inhibitory neurotransmission mostly
in the hippocampus (Dierssen, 2012). Additionally, amyloid
precursor protein (APP) is triplicated in DS and it is believed
to contribute to neurodevelopmental alterations and to trigger
the development of Alzheimer-like pathology in DS adults
(Stagni et al., 2017). As extensively reviewed elsewhere (Stagni
et al., 2017), various biochemical pathways have been causally
associated to the impairment of neurogenesis and the consequent
shift in cell destiny leading to reduced neurons and increased
percentage of astrocytes.
The first, and up to now the only available, hint of altered
purinergic signaling in DS came indirectly from the observation
that lack of sortin nexin 27 (SNX27), a PDZ-containing protein
of the endosome-associated retromer complex controlling the
trafficking of several proteins (Carlton et al., 2005), leads
to severe impairment of brain functions, including cognitive
manifestations mimicking those observed in DS (Wang et al.,
2013, 2014). Additionally, SNX27 is down-regulated in Ts65Dn
mice, the most common mouse model of DS, as a consequence
of the hyperexpression of miR-155 which is physiologically
responsible for its degradation (Wang et al., 2013, 2014).
Our research group got interested in SNX27 while searching
for the biochemical pathways responsible for the membrane-
to-cytosol recycling or intracellular degradation of the G
protein-coupled P2Y-like receptor GPR17. GPR17 responds to
both extracellular uracil nucleotides (UDP, UDP-glucose) and
cysteinyl-leukotrienes (Ciana et al., 2006). GPR17 is highly
expressed by cells of the oligodendrocyte lineage, specifically
during the transition from OPCs to immature oligodendrocytes.
After this stage, GPR17 expression must be down-regulated to
promote the generation of fully myelinating mature cells (Lecca
et al., 2008; Chen et al., 2009; Boda et al., 2011; Ceruti et al.,
2011; Fumagalli et al., 2011, 2015). In agreement with these
findings, forced overexpression of GPR17 during late stages of
differentiation leads to defective myelination in vitro and in vivo,
whereas in vivo GPR17 knock-out accelerates oligodendrocyte
myelination (Chen et al., 2009). Based on these data, we
evaluated the possible involvement of SNX27 in the fine-tuned
regulation of GPR17 membrane expression, and demonstrated
that the endocytic trafficking of the receptor is mediated by
the interaction of a type I PDZ-binding motif located at its C-
terminus with SNX27. Additionally, SNX27 knock-down in vitro
reduced GPR17 plasma membrane recycling in differentiating
oligodendrocytes while fostering their terminal maturation
(Meraviglia et al., 2016). When analyzing the brains of Ts65Dn
mice, we observed that trisomy-linked down-regulation of
SNX27 was paralleled by decreased GPR17 expression and
increased number of mature oligodendrocytes, which, however,
fail in reaching full maturation, eventually leading to brain
hypomyelination (Meraviglia et al., 2016; Figure 4).
We therefore speculate that altered GPR17 signaling and
oligodendrocyte maturation, with consequent defective axon
myelination, could contribute to the overall brain pathological
phenotype of DS, both in terms of brain structure and functions.
New Perspectives for the Identification of
Causative Genes Involved in Mental
Retardation: The Example of PANX1
The availability of innovative and automated strategies to
evaluate the presence of gene variants and mutations is
accelerating our comprehension of the genetic alterations at
the basis of rare or sporadic pathological phenotypes, such
as some forms of mental retardation. The discovery of the
first patient bearing a homozygous Pannexin 1 (Panx1) loss-of-
function gene variant associated with multisystem dysfunction
and intellectual disability has been recently published (Shao et al.,
2016). Panx1 is a membrane channel allowing the passage of
ions and small molecules, among which ATP is one of the most
common (Boyce and Swayne, 2017). In the CNS, Panx1 is highly
expressed by developing and mature neurons, and contributes
to brain development, maturation, and to synaptic plasticity
(Wicki-Stordeur et al., 2016). Thus, reduced ATP release in the
presence of mutated Panx1 could lead to defective purinergic
transmission which in turn could be responsible for alterations in
brain structures and mental retardation. It is worth mentioning
that a close relationship has been demonstrated between Panx1
and the P2X7 receptor subtype, which is crucially involved in
brain development (see Contribution of Purinergic Transmission
to the Development of the Central Nervous System). Data
demonstrate that the two proteins can physically interact (Boyce
and Swayne, 2017) and that ATP released through Panx1 in
the microenvironment of P2X7 receptor ultimately leads to its
activation. Defects in this signaling pathway can therefore have
profound impact on brain development during embryonic and
fetal life and on intellectual functions after birth.
Maternal Immune Activation and
Neurodevelopmental Abnormalities: The
Role of Purinergic Signaling
It is now increasingly recognized that inflammation is a crucial
contributor to an altered fetal brain development (Hagberg et al.,
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FIGURE 4 | Altered SNX27/GPR17 interaction and impaired myelination in a mouse model of DS. During physiological oligodendrocyte maturation, GPR17 must be
downregulated at a specific step of oligodendrocyte differentiation to allow the transition from mature to fully myelinating cells. SNX27 promotes and controls
oligodendrocyte maturation, by guiding the membrane recycling and degradation of GPR17 receptor through the binding to a type I PDZ-binding motif located at its
C-terminus. In the brains of Ts65Dn mice (an animal model of DS), trisomic miR-155 leads to SNX27 degradation, which in turn dysregulates GPR17 membrane
expression leading to its precocious downregulation. We hypothesize that this event is crucially related to the altered pattern of myelination observed in Ts65Dn mouse
brains, with reduced expression of myelin proteins, which could significantly affect cognitive functions. See text and Meraviglia et al. (2016) for details.
2015). In particular, epidemiological studies have shown that
maternal infection is an important environmental risk factor
for neurodevelopmental disorders (Boksa, 2010). In preclinical
animal models, perinatal infection has been indeed reported
to cause maternal immune activation (also called mIA) that is
associated with later appearance of autism spectrum disorder,
and schizophrenia by altering fetal brain development at critical
periods of pregnancy (Knuesel et al., 2014; Estes and McAllister,
2016; Table 1).
Although the initial prenatal insult alone may not be
enough for clinical manifestation in human, many studies
have focused on animal models of maternal infection
to investigate the causal chain of events linking immune
exposure and genetic predisposition, to neurodevelopmental
abnormalities, as extensively reviewed elsewhere (Knuesel et al.,
2014). Maternal infection is mainly mimicked by exposing
pregnant rats to either LPS, or the inflammatory viral mimetic
polyinosinic:polycytidylic acid (poly I:C) in the gestational
period or by direct intrauterin administration of LPS (Cai
et al., 2000; Bell and Hallenbeck, 2002). Immune mediators
(cytokines and chemokines), reactive oxygen or nitrogen species,
excitotoxicity, mitochondrial impairment, and altered vascular
integrity have been described to be critical contributors to
abnormal brain development in the offspring after maternal
immune activation (Hagberg et al., 2015). In particular,
microglial priming and elevation of maternal pro-inflammatory
cytokines (i.e., TNF-α, IL-6, IL1-β) have been casually linked
to dysregulation of fundamental neurodevelopment programs
(Vargas et al., 2005; Morgan et al., 2010; Upthegrove et al., 2014).
In this respect, members of the nucleotide-binding domain-like
receptor (NLR) protein family act as inflammasome sensors,
and mediate the translation of maternal immune activation
to pathologically relevant neurodevelopmental abnormalities.
Inflammasomes critically control different aspects of innate
immunity, including the release of pro-inflammatory cytokines
that induce and sustain the inflammatory response (Latz et al.,
2013). The NLRP3 inflammasome is one of the major signaling
routes that mediates the shift from innate immune activation to
inflammation in response to different pathogenic or endogenous
danger signals, including ATP (de Torre-Minguela et al., 2017).
ATP-dependent stimulation of P2X7 receptors indeed promotes
inflammasome activation, leading to caspase-1 cleavage and
release of mature IL1-β (Ferrari et al., 2006; Di Virgilio et al.,
2017). In line with this, recent data have demonstrated that both
genetic deletion and the pharmacological inhibition of P2X7
receptors mitigate schizophrenia-like behavioral changes in a
phencyclidine-induced rodent model of schizophrenia (Koványi
et al., 2016).
Another study has revealed the critical role of P2X7
receptor in affecting astrocyte-neuron cross-talk after LPS
prenatal exposure. The infection during gestation triggers
the release of ATP from astrocytes via Cx43 and Panx1
unopposed channel, resulting in increased neuronal death
mediated by P2X7 receptors and Panx1 channels (Avendano
et al., 2015).
Maternal inflammation induced by perinatal infections
can also result in preterm infants (Hagberg et al., 2012).
Diffuse perinatal white matter injuries, including periventricular
leukomalacia caused by ischemic damage, are the most
common type of brain injury in preterm infants. Pathological
demyelination and impaired oligodendrocyte maturation are
known to cause cerebral palsy, and cognitive, behavioral, and
sensory deficits as well as psychological problems later in life (van
Tilborg et al., 2016). As detailed in section Toward a Purinergic-
Based Therapy for Congenital Neurodevelopmental Disorders?,
administration of UDP-glucose, acting on different purinergic
receptors, has proven successful in improving the survival of
newly generated oligodendrocytes in neonatal rats with ischemic
Frontiers in Pharmacology | www.frontiersin.org 11 December 2017 | Volume 8 | Article 941
Fumagalli et al. Purines, Pyrimidines, and Neurodevelopmental Disorders
TABLE 2 | Purine- and pyrimidine-based pharmacological approaches to modulate congenital neurodevelopmental disorders and their functional outcomes.
Neurodevelopmental
disorder
Approach Target receptor(s) Effects References
Autism spectrum disorder Suramin (SAT-1 translational
pilot study)
P2 receptors ↑ language and social interactions
↓ repetitive behaviors
Naviaux et al.,
2017
Ketogenic diet Mainly A1 receptors (increased
activity)
↑ cognition, mood, behavior and social life Masino et al.,
2011b, 2013
HPRT deficiency SAM None ↓ self-injurious behavior Chen et al.,
2014
Ischemic periventricular
leukomalacia
UDP-glucose Activation of P2Y14 and GPR17
receptors
↑ proliferation and differentiation to mature
oligodendrocytes of glial progenitors in the
subventricular zone
Mao et al.,
2012; Li et al.,
2015
PRPS1-related disorders
(including Arts syndrome)
SAM None ↓ neurological symptoms de Brouwer
et al., 2010
Schizophrenia Strategies to upregulate
extracellular adenosine (see
text)
Mainly A1 receptors (increased
activity)
↓ psychotic symptoms Shen et al.,
2012
JNJ-47965567 Block of P2X7 receptor ↑ of social interactions
(phencyclidine-induced schizophrenia)
Koványi et al.,
2016
UMPS deficiency UMP and CMP
administration
None ↓ neurological and non-neurological
symptoms
Nyhan, 2005
periventricular leukomalacia (Mao et al., 2012; Li et al., 2015;
Table 2).
Interestingly, another approach targeting purinergic receptors
with suramin has been reported to correct the autism spectrum
disorder-like phenotype and to restore normal social behavior
in a maternal immune activation murine model of autism-
like behaviors using polyI:C exposure, and in the Fragile X
(Fmr1 knockout) model (Naviaux et al., 2013, 2015; Table 2).
These effects have been ascribed to the capability of the
anti-purinergic treatment to normalize the expression of two
purinergic receptors (P2Y2 and P2X7) and the phosphorylation
of ERK1, ERK2, and CAMKII, all of which modulate purinergic
signaling. In addition, suramin has been reported to correct the
concentrations of some altered purine metabolites (9 out of 11,
including ATP and allantoin) in the plasma of mice subjected to
maternal immune activation (Naviaux et al., 2013, 2014, 2015).
Metabolomic studies have also revealed similar alterations in
the purine and pyrimidine metabolite profile in human biofluids
(urines and plasma) of children suffering from autism spectrum
disorder (Gevi et al., 2016). Moreover, purinergic signaling
in the brain has been identified as one of the top-regulated
gene expression pathways correlated with abnormal behaviors
in children with autism spectrum disorder suggesting a key role
of purines in driving a cell danger response in these disorders
(Ginsberg et al., 2012).
Although the molecular basis of the altered purine
metabolism in murine models of autism spectrum disorder
still remains to be elucidated, these data suggest that metabolic
pathways that synthesize and catabolize purines are critical
regulatory elements in autism spectrum disorder, in accordance
with their increasingly recognized role in promoting other
neurodevelopmental and behavioral abnormalities (Micheli
et al., 2011, see sections Defects in Nucleotide Metabolism
and Toward a Purinergic-Based Therapy for Congenital
Neurodevelopmental Disorders?).
THE ADENOSINE DYSFUNCTION
HYPOTHESIS IN NEURODEVELOPMENT
Interestingly, as elegantly summarized in a previously published
review (Boison et al., 2012), it has been proposed that
dysfunctions in normal adenosine homeostasis during critical
early brain development may have important consequences on
the formation of neuronal circuitries, thus contributing to the
neurodevelopment alterations at the basis of schizophrenia (Lara
and Souza, 2000; Lara et al., 2006). In particular, abnormal
adenosine levels (consequent to brain insults, such as hypoxia,
seizures, infections, and trauma, eventually leading to ATP
breakdown or due to altered control exerted by adenosine
kinase; Cunha, 2001; Dunwiddie and Masino, 2001; Boison
et al., 2010) have been described to induce primary brain
changes. In line with these observations, administration of an
A1 adenosine receptor agonist immediately after birth leads to
ventricular enlargement and widespread gray and white matter
alterations (Turner et al., 2002), paralleled by a reduction in
A1 receptor density. Furthermore, magnetic resonance imaging
(MRI) studies in schizophrenic patients have revealed diffuse
gray and white matter changes (Davis et al., 2003), that could
be also related to early adenosine alterations. Interestingly, in the
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immature brain adenosine in mostly toxic to axons, which is in
agreement with high neuronal density and reduced arborization
in schizophrenic brain (Davis et al., 2003). These events would
lead to deficit of adenosine-mediated inhibitory actions due
to a partial loss of A1 receptors, which has been proposed to
increase brain vulnerability to damage in the adulthood. In
fact, it results in increased basal dopaminergic activity, due to
attenuation of the tonic inhibition of dopamine release, leading
to positive symptoms of the pathology (e.g., hallucinations), and
in augmented vulnerability to excitotoxic glutamate in mature
brain. On these bases, pharmacological treatments enhancing
adenosine activity could be effective for symptoms control
in schizophrenia (Shen et al., 2012; see section Toward a
Purinergic-Based Therapy for Congenital Neurodevelopmental
Disorders?).
Of note, several studies have also shown that adenosine
plays a key role in reducing multiple behavioral symptoms of
autism (Tanimura et al., 2010; Masino et al., 2011a), based
on the well-established role of this purine nucleoside as anti-
convulsant, sleep-promoter and anxiolytic (Ribeiro et al., 2002;
see section Toward a Purinergic-Based Therapy for Congenital
Neurodevelopmental Disorders? and Table 2).
TOWARD A PURINERGIC-BASED
THERAPY FOR CONGENITAL
NEURODEVELOPMENTAL DISORDERS?
Overall, the above-mentioned evidence suggests that purinergic
signaling is directly involved in many neurodevelopmental
alterations that eventually lead to severe congenital disorders.
In the case of exclusively genetic pathologies, the ideal strategy
would be to fully restore the deficits by gene therapy. This
has been successfully obtained for children affected by ADA-
SCID (see section Defects in Purine De Novo Biosynthesis
and Catabolism), by unconditioned hematopoietic stem cell
transplant (Ferrua and Aiuti, 2017), due to the predominant
peripheral manifestations of the pathology. To date, the
correction of neurodevelopment defects through genetic in utero
manipulation of defective pathways is still a matter of
debate, also due to significant ethical issues. Thus, when
modifications in enzyme and receptor activity are involved,
acting pharmacologically after birth to restore defective functions
can represent an innovative and feasible strategy to alleviate the
symptoms.
One possibility is the dietary administration of the end-
products of defective pathways. Concerning diseases linked
to altered nucleotide and nucleoside metabolism (see section
Neurodevelopmental Disorders Associated to Alterations in
Purine and Pyrimidine Metabolism), depletion of the purine
nucleotide pools observed in patients completely lacking PRPS1
or having some residual enzyme activity induces a significant
ATP starvation, that results in a strong energy impairment in
neurons. Ideally, direct brain administration of adenosine would
be the best therapeutic strategy, as it is efficiently salvaged to
corresponding nucleotides by adenosine kinase. Unfortunately,
as already mentioned (see section Neurodevelopmental Diseases
and Pyrimidine Metabolism), dietary adenosine itself is not
absorbed by the intestine, but S-adenosylmethionine (SAM) can
function as cargo to cross both the gut and the blood-brain
barriers; accordingly, it has been already successfully used to
treat some cases of Arts syndrome (see section Defects in Purine
de Novo Biosynthesis and Catabolism; de Brouwer et al., 2010).
Moreover, SAM has been demonstrated to reduce self-injurious
behavior in children with HPRT deficiency (Chen et al., 2014).
The main risk of SAM administration is the possible generation
of homocysteine with consequent vascular toxicity. Thus, its
extensive use in clinics should be carefully evaluated.
UMP and CMP administration was reported to have a
therapeutic effect in subjects with UMPS deficiency, likely
due to dephosphorylation to their respective nucleosides, able
to cross the plasma membrane. Uridine supplementation was
also shown to provide a good source for salvage to UMP,
displaying remarkable effects on both neurological and non-
neurological symptoms and even complete remission in patients
with pyrimidine deficiency (Nyhan, 2005). Conversely, uracil was
ineffective.
Based on the known role of purines in promoting myelination
(see section Contribution of Purinergic Transmission to the
development of the Central Nervous System), the presence
of congenital white matter abnormalities is suggestive of
alterations of specific purinergic signaling pathways. Of note,
the long-term prognosis of neonatal rats with cerebral white
matter injury due to ischemic periventricular leukomalacia (see
section Maternal Immune Activation and Neurodevelopmental
Abnormalities: the Role of Purinergic Signaling) was significantly
improved by the intraperitoneal injection of UDP-glucose, an
endogenous agonist acting on different purinergic receptor
subtypes, including GPR17 receptor (a key determinant of
oligodendrocyte maturation and differentiation; see section
Involvement of the Purinergic System in Brain Alterations
Observed in Down Syndrome). UDP-glucose stimulated the
proliferation of glial progenitor cells derived from both the
ventricular/subventricular zone andwhitematter, promoted their
differentiation into mature oligodendrocytes, and raised the
survival rate of newly generated glial cells (Mao et al., 2012; Li
et al., 2015). Based on the observed dysfunctions in the pattern
of myelination accompanied by reduced GPR17 expression in
brains from a mouse model of DS (see section Involvement
of the Purinergic System in Brain Alterations Observed in
Down Syndrome), it can be speculated that the pharmacological
manipulation of this receptor could prove effective in reducing
DS-linked intellectual disabilities.
Autism spectrum disorder is currently lacking
pharmacological approaches, also due to the wide range of
associated symptoms and clinical manifestations. Based on
the promising findings on a mouse model of the disease (see
section Maternal Immune Activation and Neurodevelopmental
Abnormalities: the Role of Purinergic Signaling), a recent
small, phase I/II, randomized clinical trial has been carried
out to examine the safety and activity of a single intravenous
low-dose of suramin in children with autism spectrum disorder
D. The Suramin Autism Treatment-1 (called SAT-1) was a
double-blind, placebo controlled, translational pilot study that
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showed improvements in language, and social interaction and
decreased repetitive behaviors (Naviaux et al., 2017). Despite
some limitations of this study, included its small size and the
suboptimal timing of the outcome measurements, and the
need to confirm the results in a larger number of children
(Naviaux et al., 2017), the SAT-1 trial highlighted suramin as an
encouraging innovative approach for autism spectrum disorder
therapy.
Furthermore, results from diverse clinical trials have
shown that a ketogenic diet (a high fat, low carbohydrate,
adequate protein formula which promotes the use of ketones,
rather than glucose, for energy production) can improve
cognition, mood, behavior, and social life in autism spectrum
disorder patients. Interestingly, these positive effects have
been also ascribed to an augmented action of adenosine at A1
receptors, leading to opening of K+ channels and membrane
hyperpolarization/reduced excitability (Kawamura et al., 2010;
Masino et al., 2011b). Currently, two independent studies on
the effects of an intermittent ketogenic diet on the behavior of
children with autism spectrum disorder have been performed,
and results indicated that the most significant improvements
were noticed in patients showing only mild autistic behavior
(Herbert and Buckley, 2013; Masino et al., 2013).
Likewise, patients affected by schizophrenia would benefit
from increased adenosine receptor activity (see section The
Adenosine Dysfunction Hypothesis in Neurodevelopment).
Promising strategies to upregulate extracellular adenosine are
represented by the inhibition of adenosine kinase (e.g., with
direct inhibitors, ketogenic diet that downregulate the enzyme,
or allopurinol and dipyridamole, which augment extracellular
adenosine by inhibiting its degradation and reuptake) and by the
use of brain implants of adenosine-releasing cells (Shen et al.,
2012).
It is therefore evident that encouraging attempts to
pharmacologically target the purinergic system in disorders
associated to neurodevelopment have been already performed
(see Table 2 for summary). Future research should now move
to different directions: (i) to implement the knowledge on the
physiological role played by purines/pyrimidines in controlling
and promoting CNS development (see section Contribution
of Purinergic Transmission to the Development of the Central
Nervous System); (ii) to highlight the contribution to altered
neurodevelopmental stages of dysfunction/mutations of specific
enzymes or receptor subtypes and of their cross-talk [e.g., the
TNAP enzyme and the P2X7-Pax1 complex; see sections Defects
in Purine Metabolism and Abnormal Brain Development: the
Case of Tissue Non Specific Alkaline Phosphatase (TNAP) and
New Perspectives for the Identification of Causative Genes
Involved in Mental Retardation: the Example of PANX1]; (iii)
to foster the design and synthesis of more selective, potent, and
brain permeable ligands, and their evaluation in pre-clinical
animal models of the diseases. The goal to cure congenital
neurodevelopmental disorders through the purinergic system
will be only achieved thanks to the collaborations of different and
complementary scientific expertizes, including neuroscience,
neurobiology, genetics, physiology, neuropharmacology, and
medicinal chemistry.
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